The IDH2 (R140Q) NRAS (G13R) population shrinks to 8% of the tumor at the same relapse time point at which the triple-mutant IDH2 (R140Q) NRAS (G13R) ASXL1 (G646fs) clone expands to 64%. This evidence concerns the gene ASXL1 and neoplasm.